Empagliflozin treatment is also associated with reduced stroke size in SCD mice suggesting SGLT‐2 inhibitor treatment may be beneficial with regard to both anaemia and vascular complications in SCD patients. The gene discussed is SLC5A2; the disease is Schnyder corneal dystrophy.